Gene Therapy Approval Standards: Available Treatments Influence US FDA’s View On Durability

 
• By Sue Sutter

CBER’s Peter Marks says agency assesses the importance of durability of effect differently for a gene therapy that treats a disease that has no other available therapies versus a condition for which there are multiple approved treatments. Marks’ comments shed more light on the complete response letter for BioMarin’s hemophilia gene therapy Roctavian.

two benches in a park in autumn that point in different directons
US FDA's view on gene therapy effect durability depends upon the disease and treatment landscape. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies